Article info
Editorial
Pirfenidone for IPF: pro/con debate; the ‘con’ viewpoint
- Correspondence to Dr David Thickett, Centre for Translational Inflammation and Fibrosis Research, School of Clinical and Experimental Medicine, University of Birmingham, UK; d.thickett{at}bham.ac.uk
Citation
Pirfenidone for IPF: pro/con debate; the ‘con’ viewpoint
Publication history
- First published March 5, 2013.
Online issue publication
September 01, 2022
Article Versions
- Previous version (29 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions